Pharvaris Bundle
Who owns Pharvaris?
In February 2024 Pharvaris N.V. surged after positive Phase 2 CHAPTER-1 prophylaxis results for deucrictibant, prompting institutional interest ahead of Phase 3. Founded in 2015 and based in Leiden with U.S. operations, the company targets oral HAE therapies via the bradykinin B2 receptor.
As of mid-2025 Pharvaris is Nasdaq-listed (PHVS), clinical-stage with no approved products and a cash runway into 2026; ownership is concentrated among life-science institutions, crossover funds, founders and management, influencing strategy as deucrictibant advances. See Pharvaris Porter's Five Forces Analysis
Who Founded Pharvaris?
Founders and early ownership of Pharvaris were concentrated among scientific and executive founders, with structured vesting, protective provisions, and early angel participation shaping initial control and cap table dynamics.
Founding team
Co-founded in 2015 by Berndt U. Pashnick, Jochen Knolle, PhD, Barbara Yanni, JD, and Tom de Vries, with technical hires from Shire/ViroPharma networks.
Equity structure
Common equity concentrated with founders, typically subject to 4-year vesting and a 1-year cliff, plus founder lock-ups and NV shareholder agreements.
Seed investors
Seed round included friends-and-family and European angels from Leiden/Basel biotech circles, followed by an institutional seed extension.
Control pre-Series A
Founders collectively held a majority of common shares pre-Series A with standard ROFRs and co-sale rights protecting insider stakes.
No early disputes
No publicized founder disputes or buyouts occurred in the first two years; equity distribution aligned with scientific leadership and oral-B2 program risk.
Strategic architecture
Early IP and BD strategy were driven by Yanni and technical founders, aligning ownership with program priorities and partner-readiness.
Founders retained operational control and meaningful ownership stakes through protective shareholder provisions while preparing for subsequent institutional rounds and board composition changes.
Key facts and implications
Early ownership and governance that shaped Pharvaris' path to institutional financing and eventual public listing considerations:
- Founding year: 2015
- Founders: Berndt U. Pashnick; Jochen Knolle, PhD; Barbara Yanni, JD; Tom de Vries
- Vesting terms: standard 4-year vesting with 1-year cliff
- Seed sources: friends-and-family, European angels (Leiden/Basel), institutional seed extension
For deeper strategic context and investor implications, see Marketing Strategy of Pharvaris
Pharvaris SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Pharvaris’s Ownership Changed Over Time?
Key events reshaping Pharvaris ownership include early Series A/B VC entry (2016–2018), crossover financing ahead of the IPO (2019–2020), the Nasdaq listing in February 2021, and follow-on/ATM raises after a 2023 FDA clinical hold was lifted in 2024—driving a shift toward institutional and specialist shareholders.
| Period | Ownership Changes | Key Stakeholders |
|---|---|---|
| 2016–2018 | Series A/B rounds introduced preferred shares with anti-dilution and board rights | Life-science VCs and crossover-style investors (EU rare-disease specialists) |
| 2019–2020 | Crossover financing expanded institutional base and increased preferred ownership | U.S. crossover funds and institutional pre-IPO investors |
| Feb 2021 IPO | Raised approximately $165–190M gross; market cap near $700–800M | U.S. institutions, index funds, and specialist life-science investors |
| 2023–2025 | Follow-on offerings and ATM programs after 2024 clinical-hold lift; float and secondary liquidity rose | RA Capital, BVF Partners, OrbiMed, Perceptive, Vanguard, BlackRock; insiders mid-single-digit |
Pharvaris ownership evolved from VC-led preferred shareholdings to a distributed, specialist-heavy public register; institutional ownership exceeds 70% by mid-2025 with no single holder above 20%, and founders diluted to low-single-digit stakes.
Ownership milestones and implications
Key ownership shifts enabled larger Phase 3 programs and stronger governance via investor-directors while changing shareholder composition toward institutions and index funds.
- 2016–2018: VC preferred rounds set board and anti-dilution protections
- 2021 IPO: public listing moved control toward U.S. institutions and funds
- 2023–2024: clinical hold lifted; follow-on raises brought specialist biotech investors
- Mid-2025: institutional ownership > 70%, multiple holders in the 5–15% range
For additional context on revenue and strategic positioning that influenced investor interest, see Revenue Streams & Business Model of Pharvaris
Pharvaris PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Pharvaris’s Board?
Pharvaris' board of directors (2024–2025) combines independent biopharma operators, regulatory experts and investor representatives from leading life‑science funds, alongside company executives; composition reflects alignment with clinical and financing milestones and dispersed institutional ownership.
| Director | Role / Background | Representative of |
|---|---|---|
| Independent Director A | Former large‑cap rare‑disease CEO; regulatory experience | Independent |
| Independent Director B | Regulatory affairs expert; ex‑EMA/US FDA advisor | Independent |
| Investor‑Nominated Director C | Life‑science fund partner; crossover investor (2020) | Top institutional holder |
| Investor‑Nominated Director D | VC partner involved in 2021 IPO cohort | Institutional holder |
| Executive Director (CEO) | Company management; operational lead | Management |
The company uses a one‑share‑one‑vote capital structure with no dual‑class shares, no founder super‑voting rights and no golden share; voting power is institutionally dispersed and governance influence maps to audit, compensation and nominating committee roles rather than a single controlling owner. Recent governance actions through mid‑2025 show routine say‑on‑pay and director elections passing with >70% support, and no disclosed proxy contests or activist campaigns.
Board and Voting Highlights
Board composition ties major Pharvaris shareholders to clinical and financing strategy; institutional investors dominate voting blocks but no controlling stake exists.
- One‑share‑one‑vote structure — no dual‑class or golden share
- Investor‑nominated directors represent top institutional holders from 2020–2021 financing
- Routine governance votes passed with >70% support through mid‑2025
- No proxy contests or activist campaigns disclosed through 2025
For background on corporate evolution and key investors, see Brief History of Pharvaris.
Pharvaris Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Pharvaris’s Ownership Landscape?
Since 2023 Pharvaris ownership shifted from concentrated early holders to broader institutional and passive investor participation, driven by clinical/regulatory catalysts and follow-on financings that extended runway into 2026 while modestly diluting insiders.
| Period | Key Ownership Change | Impact |
|---|---|---|
| 2023 | FDA hold; selling pressure from specialists and some VCs | Market cap decline; passive index weights fell |
| 2024 | FDA hold lifted; positive CHAPTER-1 data; follow-on financing | Institutions increased ownership; market cap recovery; passive ownership rose |
| 2025 (YTD) | Additional financing; insiders reduced to low-single digits; institutions >70% | Broader shareholder base; modest dilution; no buybacks or M&A |
Ownership trends show typical late-stage rare-disease biotech patterns: founder dilution, rising specialist institutional concentration, and increased passive index stakes from Vanguard, BlackRock and State Street as market cap rebounded.
Capital raises and runway
Follow-on financings in 2024–2025 raised enough cash to carry operations into 2026, reducing immediate dilution pressure on future NDA/MAA filings.
Institutional concentration
Institutions now hold >70% of shares; passive index ownership increased materially with market cap gains.
Insider and VC activity
Insider ownership declined to low-single digits as some early VCs distributed or sold down positions during secondary offerings.
Strategic outlook
Management signals readiness for commercialization partnerships or ex-U.S. licensing after Phase 3; no dual-class or control shifts planned. See Competitors Landscape of Pharvaris for context on market positioning and investor interest.
Pharvaris Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Pharvaris Company?
- What is Competitive Landscape of Pharvaris Company?
- What is Growth Strategy and Future Prospects of Pharvaris Company?
- How Does Pharvaris Company Work?
- What is Sales and Marketing Strategy of Pharvaris Company?
- What are Mission Vision & Core Values of Pharvaris Company?
- What is Customer Demographics and Target Market of Pharvaris Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.